Login / Signup

Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19.

Jacek SkarbinskiLiyan LiuVennis HongLaura B AmsdenBruce H FiremanVincent M YauDevin IncertiLei QianHeidi FischerBradley K AckersonSally F ShawSara Y Tartof
Published in: BMJ open (2022)
Among mechanically ventilated patients with COVID-19, the risk of death in the 28-day follow-up period was similar, but time-to-extubation and time-to-hospital-discharge were longer in patients who received tocilizumab within 10 days of initiation of IMV compared with patients who did not receive tocilizumab.
Keyphrases